REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Follow-Up Questions
Who is the CEO of Regenxbio Inc?
Mr. Curran Simpson is the President of Regenxbio Inc, joining the firm since 2015.
What is the price performance of RGNX stock?
The current price of RGNX is $12.47, it has increased 6.3% in the last trading day.
What are the primary business themes or industries for Regenxbio Inc?
Regenxbio Inc belongs to Biotechnology industry and the sector is Health Care
What is Regenxbio Inc market cap?
Regenxbio Inc's current market cap is $629.8M
Is Regenxbio Inc a buy, sell, or hold?
According to wall street analysts, 15 analysts have made analyst ratings for Regenxbio Inc, including 6 strong buy, 10 buy, 2 hold, 0 sell, and 6 strong sell
